Attachment 12.3 Smokeless tobacco and harm reduction

By Dr Coral Gartner, University of Queensland

A12.3.0 Introduction

There are many different forms of smokeless tobacco, including chewing tobacco, oral snuff and nasal snuff. Non-traditional forms include compressed tobacco lozenges and dissolvable strips. The health risks associated with smokeless tobacco products vary considerably between types of products and within the same class of product.1, 2 The smokeless tobacco products that are most relevant to the harm reduction debate are those that have been produced to be relatively low in toxins, such as carcinogenic nitrosamines.1–5

A12.3.1 The 'Swedish experience'

Sweden has a similar prevalence of tobacco use to its neighbours, but one of the world's lowest tobacco-attributable mortality rates. Some observers have suggested this phenomenon, known as 'the Swedish experience' is explained by the increasing use of smokeless tobacco, a trend that has corresponded with a decline in smoking prevalence, particularly among Swedish men who are the greatest users of smokeless tobacco.6–8 However, this interpretation has been debated.9

The most common form of smokeless tobacco used in Sweden is a moist oral snuff called snus, which is available either as loose tobacco or pre-packaged portions that resemble teabags. Unlike other smokeless tobacco products marketed in the US and other countries, snus is pasteurised rather than fermented and stored under refrigeration to minimise bacterial growth. These processes greatly reduce the formation of nitrosamines, the main carcinogens in tobacco. This, and the absence of the combustion products associated with smoking (e.g. carbon monoxide, small particulate matter) reduces the risks of cardiovascular disease, chronic obstructive pulmonary disease and cancer compared to smoking. Unlike cigarettes, snus does not produce secondhand smoke or carry a risk of causing accidental fires.

Long-term prospective cohort studies have observed a lower risk of many tobacco-related diseases and overall lower mortality in snus users compared to smokers.8,10–13 Snus use appears to carry some residual risks, albeit lower than for smoking, of pancreatic cancer,11,14,15 cardiovascular disease16,17 and possibly diabetes18,19 compared with no tobacco use. Snus use is also associated with dental disease and gum lesions, called leukoplakia, but these appear to disappear on discontinuation of use.20

In Sweden, among people who have ever smoked regularly, those who use snus are more likely to have quit smoking than those who do not.7,21,22 A similar relationship is also seen in Norway among currently daily and former snus users.23 The Swedish experience has prompted some researchers to suggest that smokers who are unable to quit should use low nitrosamine smokeless tobacco products, such as snus, to reduce tobacco-related harm.24 This proposal is contentious.25–27

Some health professionals do not feel that the existing epidemiological studies showing a lower risk of tobacco-related disease in snus users are sufficient to support snus use as a harm reduction stragey. Others are concerned that the difference in potential harm between snus and smoking has not have been fully described in existing studies. Some believe that any health risk from snus, no matter how small, is too great for its use to be encouraged. However, the difference in healthy life expectancy and overall mortality risk between smokers who quit all tobacco and smokers who switch to low nitrosamine smokeless forms appears to be small.28,29 Sweden has also achieved substantial reductions in tobacco-attributable mortality despite a high prevalence of snus use among men.

A12.3.2 Cultural adaptability

Snus has had an extensive traditional use in Sweden, where it was known as 'the poor man's luxury'. Whether the Swedish experience would transfer to Australia, which has never had a significant smokeless tobacco tradition, is uncertain. A growing smokeless tobacco market in Australia during the 1980s was halted by the introduction of a commercial sales ban in 1991, but it is unknown whether these products would have become widespread without the ban.30 A survey of Australian smokers in 2008 found that around half were interested in purchasing low-nitrosamine varieties of smokeless tobacco.31 However, the survey participants were only provided with pictures and written descriptions of the products rather than samples to try, and most had no previous experience of using smokeless tobacco. In contrast only 13% of smokers in a Californian survey stated they would probably or definitely switch to smokeless tobacco if they thought it was less harmful than smoking.32

There are also behavioural aspects of smoking that may not be adequately replaced by snus use. For example, smoking offers something to do with the hands and is easy to do while engaging in other social activities such as drinking and talking. Snus is simply placed under the top lip and left there until it is removed. Talking and drinking while using snus requires more skill than smoking to keep the tobacco portion in place. The small bulge visible in the upper lip during snus use may also lack the supposed glamour of smoking.

A12.3.3 Ethical issues

Low nitrosamine smokeless tobacco products are not harmless and can be as addictive as smoking.33 Many health professionals feel it is unethical to promote the use of a substance that offers no direct benefit to the user (the indirect benefit is the absence of smoking), is addictive and still carries risks. Proponents of tobacco harm reduction with smokeless tobacco counter that it is unethical to deny smokers access to products with substantially lower risks than smoking and to deny them accurate information about the benefits of switching to them, particularly as cigarettes, the most harmful tobacco product, are readily available.34

Opponents argue that quitting all tobacco use is the only health advice that doesn't carry any risk. Proponents argue that many smokers fail to follow this advice and that 'quit' or 'keep smoking', sometimes described as 'quit or die', should not be the only options available.35 While it is debatable whether health professionals should recommend low nitrosamine smokeless tobacco products to smokers, it is arguably unethical to provide inaccurate information about the relative harms of these products and cigarettes due to the mistrust such misinformation can create.36, 37

The lower harmfulness of low nitrosamine smokeless tobacco compared with cigarettes is likely to be an important motivator for smokers to switch products. For example, in a survey of Australian smokeless tobacco users, just over half stated they used smokeless tobacco because it was less harmful than smoking 30 and users of non-cigarette tobacco products are more likely to believe they are less harmful than cigarettes than non-users.38–40 Surveys of smokers in Australia, Canada, the UK and the US suggest that few smokers believe that smokeless tobacco is less harmful than cigarettes.38,41 Misperceptions about the relative harmfulness of smokeless tobacco products compared with cigarettes could be an important barrier to smokers switching to these less-harmful products. The challenge is avoiding messages that products like snus are 'less harmful' being misinterpreted as meaning that they are 'harmless'.

A12.3.4 Individual and population level harm

Using low nitrosamine smokeless tobacco products may reduce tobacco-related disease in individual smokers who make the switch, but widespread use could still result in population level harm in a number of ways. Firstly, if these products proved more popular among non-smokers than smokers, then overall harm could increase. Secondly, their promotion could keep current smokers smoking (instead of quitting) or lead some non-smokers to commence smoking. This is the most likely way in which smokeless tobacco promotion could produce population harm because the large difference in health risk between smoking and low nitrosamine smokeless tobacco use means that a very large number of non-smokers need to use these products to offset the health gain achieved from a smoker switching to them.25,42 In Sweden, snus use very rarely leads to smoking in non-smokers.7 It is unknown whether similar patterns of use would occur in Australia.

Tobacco manufacturers have argued that they should be able to market and promote reduced harm smokeless tobacco products in order to inform smokers of the benefits of switching. This is an important issue because if these products are to have a population level benefit, a sufficient number of smokers need to make the switch. However, promotion of smokeless tobacco via tobacco industry advertising may increase overall tobacco use, possibly including smoking among current non-smokers. Some cigarette manufacturers have also produced 'snus versions' of their most popular brands of cigarettes.43 How to allow these products to be promoted for tobacco harm reduction without allowing the promotion of the corresponding cigarette brand would be a challenge.

In countries where tobacco advertising is allowed, cigarette manufacturers have promoted dual use of smokeless and smoked tobacco products as a way to get around public smoking bans.44 Such 'dual use' could reduce or even negate any health benefit from snus use by deterring quitting. Public smoking bans not only protect non-smokers from environmental tobacco smoke, but have the added benefit of encouraging smokers to quit due to the inconvenience these bans produce. Some of these quitters may therefore be encouraged to keep smoking as they can get through the inconvenient times with a short-term alternative.45

In Norway, while current daily or former snus use is associated with quitting smoking, current occasional snus use is not.23 This may be evidence of a pattern of dual use that deters quitting smoking. Alternatively, these dual users may be in a process of gradually moving from one product to another or of quitting all tobacco use. In the US and Sweden, dual use of smoked and smokeless tobacco is uncommon and does not appear to be a stable pattern of tobacco use.46,47 Some harm reduction advocates have suggested that dual use is not necessarily a negative if it encourages smokers to try smokeless tobacco and leads to some switching completely. Whether this is a likely outcome remains to be seen. Clearly, addressing the need to inform inveterate smokers of the benefits of switching to low nitrosamine smokeless tobacco without deterring would-be quitters or encouraging smoking in non-smokers requires careful regulation of information to avoid these potential negative consequences.

A12.3.5 An unnecessary distraction?

Some tobacco control professionals view tobacco harm reduction with smokeless tobacco as a distraction from the main task of encouraging smokers to quit tobacco use and discouraging uptake.25 Tobacco smoking, they point out, has declined in Australia without these products. Supporters of harm reduction argue that it offers an additional strategy that may hasten the decline in smoking and may reach those smokers who have been resistant to traditional tobacco control strategies or have been unable to quit tobacco use despite repeated efforts.31,48

A12.3.6 What about 'clean' forms of nicotine?

Nicotine replacement therapy (NRT) products, such as gum, lozenges or inhalers, have also been suggested as a long-term alternative to smoking. Because these present lower risk than smokeless tobacco, it has been argued that there is no need for smokeless tobacco products as a harm reduction alternative.

This argument ignores the possibility that smokeless tobacco may be more attractive to smokers than NRT. Smokeless tobacco is a purely recreational tobacco product that can deliver nicotine in similar amounts to the user as smoking. It may, therefore, be a better substitute for cigarettes for smokers who want to continue using tobacco recreationally. NRT is also primarily marketed as a medicine for short-term assistance during cessation. Currently available NRT products are low dose, which prevents them from providing a sufficient 'buzz' for smokers who want to use nicotine recreationally. Higher dose, recreational, 'clean' nicotine products face substantial regulatory barriers because of their addictiveness. Australia's drugs and poisons regulatory system also does not provide for nicotine to be sold for recreational use, unless it is contained within tobacco intended for smoking.49 Pharmaceutical companies, who manufacture NRT, are unlikely to see the marketing of a recreational, addictive product as their core business. Pharmaceutical companies may also be concerned that long-term use of high-dose nicotine products may carry a higher health risk than short-term use of low-dose NRT, which has been established as safe.

In Sweden and Norway, snus is a more popular smoking cessation aid than NRT gum or patches and smokers who use snus are more likely to quit than smokers who use NRT.7,22,50–52 Among the possible reasons for this greater popularity and higher success rate are the social acceptance of snus use in Sweden, its lower cost (before 2007, snus was taxed at a lower rate than cigarettes), the higher nicotine delivery from snus compared to NRT, and possibly longer use of snus after quitting compared with NRT. Using NRT to quit smoking may also be stigmatised by some smokers who see the use of a medication to quit as a sign of drug addiction. Snus, which is not a medication, may be seen as a 'smarter choice' rather than a sign of weakness. As uptake of NRT in Australia remains relatively low,53 a product that may be more attractive to smokers and more effective, even if marginally riskier, could increase the number of quitters and therefore produce a greater population level benefit.

Smokeless tobacco products appear to be less effective at reducing abstinence symptoms than cigarettes.54,55 However, some small-scale trials suggest that smokers may prefer moist oral snuff over NRT and that snuff reduces cigarette cravings more than NRT.56,57 There is also some evidence from population surveys that switching to smokeless tobacco may be more effective than using NRT.7,51,58 There is little evidence from clinical trials available. A small trial found that smokers who were given smokeless tobacco products reduced their cigarette intake and increased their interest in quitting smoking compared with those who were not given these products.59 A survey of Australian smokers assessed the potential impact of making low nitrosamine smokeless tobacco available at a lower cost than cigarettes by asking the smokers what they would do (continue smoking, quit or switch to smokeless tobacco) under different policy scenarios.31 The option of purchasing smokeless tobacco at a lower cost than cigarettes combined with a substantial price increase on cigarettes resulted in more smokers stating they would stop smoking than if the cigarette price increase was not combined with availability of smokeless tobacco. The option of switching to smokeless tobacco appeared most attractive to those who were resistant to quitting rather than those who indicated they would quit with just a price increase alone. These results suggest that a lower tax on smokeless tobacco compared with smoked tobacco could produce a greater reduction in the number of smokers than simply increasing cigarette taxes. Similarly, a Californian survey found that smokers with greater intentions of quitting were less likely to be interested in switching to smokeless tobacco, but smokers who were trying to cut down their cigarette intake and smokers who had made unsuccessful quit attempts were more likely to be interested in switching to smokeless tobacco.32 However, larger trials are needed to confirm these survey and pilot study results and to determine whether the option of using smokeless tobacco translates to fewer smokers without detrimental effects on quitting.

A12.3.7 Can Australian smokers legally access smokeless tobacco for harm reduction?

Current federal legislation prohibits the commercial sale of smokeless tobacco within Australia. Importation for personal use is permitted. This regulatory situation allows for current users and smokers to access smokeless tobacco products while deterring non-tobacco users (particularly youth) from commencing.60 Importers face delays between ordering and receiving their smokeless tobacco products due to shipping and variable processing times by the Australian Customs and Border Protection Service. They must also pay tobacco duty on their products before they can be collected. Restrictions on posting of tobacco products through the US Postal Service since 2010 have further reduced access.61 Compared with the convenience of purchasing cigarettes, these barriers mean that only highly motivated users are likely to import these products. Some researchers have suggested that for low nitrosamine smokeless tobacco to be a realistic harm reduction option for most Australian smokers, restricted domestic sales would need to be allowed to recommence.30,62

A12.3.8 What should the public health response be?

The epidemiological evidence and the Swedish experience suggest that low nitrosamine smokeless tobacco may be an important tobacco harm reduction opportunity.62 With uncertainty around its potential effect on other tobacco control policies, most Australian commentators have been cautious about such proposals.63

Recent news and research

For recent news items and research on this topic, click here (Last updated March 2018)  


1. Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I and Hecht SS. Changing smokeless tobacco products: new tobacco delivery systems. American Journal of Preventive Medicine 2007;33(suppl. 6 ):S368-S78. Available from:

2. Stepanov I, Jensen J, Hatsukami D and Hecht SS. Tobacco-specific nitrosamines in new tobacco products. Nicotine & Tobacco Research 2006;8(2):309-13. Available from:

3. Hecht SS, Stepanov I and Hatsukami DK. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products [Letter]. Tobacco Control 2010:doi: 10.1136/tc.2010.037648. Available from:

4. Stepanov I, Jensen J, Hatsukami D and Hecht S. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine & Tobacco Research 2008;10(12):1773-82. Available from:

5. Stepanov I, Villalta P, Knezevich A, Jensen J, Hatsukami D and Hecht S. Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry. Chemical Research in Toxicology 2010;23(1):66-73. Available from:

6. Ramström LM. Snuff: an alternative nicotine delivery system. In Ferrence, R, et al., eds, In: Nicotine and Public Health. Washington, DC: American Public Health Association, 2000.

7. Ramström LM and Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tobacco Control 2006;15(3):210-14. Available from:

8. Foulds J, Ramström L, Burke M and Fagerström K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control 2003;12(4):349-59. Available from:

9. Tomar SL, Connolly GN, Wilkenfeld J and Henningfield JE. Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts? Tobacco Control 2003;12(4):368-71. Available from:

10. Critchley JA and Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. European Journal of Cardiovascular Prevention and Rehabilitation 2004;11(2):101-12. Available from:

11. Luo J, Ye W, Zendehdel K, Adami J, Adami H-O, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369:In press. Available from:

12. Carlens C, Hergens M-P, Grunewald J, Ekbom A, Eklund A, Olgart Höglund C, et al. Smoking, use of moist snuff and risk of chronic inflammatory diseases. American Journal of Respiratory and Critical Care Medicine 2010;181(11):1217-22. Available from:

13. Hansson J, Pedersen NL, Galanti MR, Andersson T, Ahlbom A, Hallqvist J, et al. Use of snus and risk for cardiovascular disease: results from the Swedish Twin Registry. Journal of Internal Medicine 2009;265(6):717-24. Available from:

14. Boffetta P, Aagnes B, Weiderpass E and Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. International Journal of Cancer 2005;114(6):992-5. Available from:

15. Boffetta P, Hecht S, Gray N, Gupta P and Straif K. Smokeless tobacco and cancer. The Lancet Oncology 2008;9(7):667-75. Available from:

16. Boffetta P and Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. British Medical Journal (Clinical Research ed) 2009;339:b3060. Available from:

17. Bolinder G, Alfredsson L, Englund A and de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. American Journal of Public Health 1994;84(3):399-404. Available from:

18. Persson P-G, Carlsson S, Svanstrom L, Ostenson C-G, Efendic S and Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. Journal of Internal Medicine 2000;248(2):103-10. Available from:

19. Eliasson M, Asplund K, Nasic S and Rodu B. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes amongst men: the northern Sweden MONICA study. Journal of Internal Medicine 2004;256(2):101-10. Available from:

20. Larsson A, Axell T and Andersson G. Reversibility of snuff dippers' lesion in Swedish moist snuff users: a clinical and histologic follow-up study. Journal of Oral Pathology and Medicine 1991;20(6):258-64. Available from:

21. Stenbeck M, Hagquist C and Rosén M. The association of snus and smoking behavior: a cohort analysis of Swedish males in the 1990s. Addiction 2009;104(9):1579-85. Available from:;jsessionid=bo161tig5es6k.alexandra

22. Gilljam H and Galanti MR. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. Addiction 2003;98(9):1183-9. Available from:

23. Lund KE, Scheffels J and McNeill A. The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studies. Addiction 2010;106(1):162-7. Available from:

24. Hall WD and Gartner CE. Supping with the Devil? Promoting tobacco harm reduction using low nitrosamine smokeless tobacco products. Public Health 2009;123(3):287-91. Available from:

25. Gartner CE, Hall WD, Chapman S and Freeman B. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? . PLoS Medicine 2007;4(7):e185. Available from:

26. Britton J. Should doctors advocate snus and other nicotine replacements? Yes. British Medical Journal 2008;336(7640):358. Available from:

27. Macara AW. Should doctors advocate snus and other nicotine replacements? No. British Medical Journal 2008;336(7640):359. Available from:

28. Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL and Lim SS. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007;369(9578):2010-14. Available from:

29. Henley SJ, Connell CJ, Richter P, Husten C, Pechacek T, Calle EE, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tobacco Control 2007;16(1):22-8. Available from:

30. Gartner CE and Hall WD. Smokeless tobacco use in Australia. Drug and Alcohol Review 2009;28:284–91.

31. Gartner CE, Jimenez-Soto EV, Borland R, O'Connor RJ and Hall WD. Are Australian smokers interested in using low-nitrosamine smokeless tobacco for harm reduction? Tobacco Control 2010;19(6):451-6. Available from:

32. Timberlake DS. Are smokers receptive to using smokeless tobacco as a substitute? Preventive Medicine 2009;49:229-32. Available from:

33. Post A, Gilljam H, Rosendahl I, Bremberg S and Galanti MR. Symptoms of nicotine dependence in a cohort of Swedish youths: a comparison between smokers, smokeless tobacco users and dual tobacco users. Addiction 2010;105(4):740-6. Available from:

34. Kozlowski LT. Harm reduction, public health, and human rights: smokers have a right to be informed of significant harm reduction options. Nicotine and Tobacco Research 2002;4(suppl. 2):S55-S60. Available from:

35. Fagerström K. Quit or Die: nothing in between? Respiration 2002;69(5):387–88.

36. Kozlowski LT. First, tell the truth: a dialogue on human rights, deception, and the use of smokeless tobacco as a substitute for cigarettes. Tobacco Control 2003;12(1):34-6. Available from:

37. Waterbor JW, Adams RM, Robinson JM, Crabtree FG, Accortt NA and Gilliland MJ. Disparities between public health educational materials and the scientific evidence that smokeless tobacco use causes cancer. Journal of Cancer Education 2004;19(1):17-28. Available from:

38. O'Connor RJ, McNeill A, Borland R, Hammond D, King B, Boudreau C, et al. Smokers' beliefs about the relative safety of other tobacco products: findings from the ITC Collaboration. Nicotine & Tobacco Research 2007;9(10):1033-42. Available from:

39. Øverland S, Hetland J and Aarø LE. Relative harm of snus and cigarettes: what do Norwegian adolescents say? Tobacco Control 2008:doi:10.1136/tc.2008.026997 Available from:

40. Wikmans T and Ramström L. Harm perception among Swedish daily smokers regarding nicotine, NRT-products and Swedish Snus. Tobacco Induced Diseases 2010;8(9):doi:10.1186/1617-9625-8-9. Available from:

41. O'Connor RJ, Hyland A, Giovino GA, Fong GT and Cummings KM. Smoker awareness of and beliefs about supposedly less-harmful tobacco products. American Journal of Preventive Medicine 2005;29(2):85-90. Available from:

42. Tobacco Advisory Group of the Royal College of Physicians. Protecting Smokers, Saving Lives: The Case for a Tobacco and Nicotine Regulatory Authority. London: Royal College of Physicians of London, 2002.

43. McNeill A and Sweanor D. Beneficence or maleficence–big tobacco and smokeless products. Addiction 2009;104(2):167-8. Available from:

44. Carpenter CM, Connolly GN, Ayo-Yusuf OA and Waynem GF. Developing smokeless tobacco products for smokers: an examination of tobacco industry documents. Tobacco Control 2009;18(1):54-9. Available from:

45. Mejia AB and Ling PM. Tobacco industry consumer research on smokeless tobacco users and product development. American Journal of Public Health 2010;100:78-87. Available from:

46. Frost-Pineda K, Appleton S, Fisher M, Fox K and Gaworski CL. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction? Nicotine & Tobacco Research 2010;12(11):1055-67. Available from:

47. Tomar SL, Alpert HR and Connolly GN. Patterns of dual use of cigarettes and smokeless tobacco among US males: findings from national surveys. Tobacco Control 2010;19:104-9. Available from:

48. Hall W and West R. Thinking about the unthinkable: a de facto prohibition on smoked tobacco products. Addiction 2008;103(6):873-4. Available from:

49. Poisons Standard 2010, Federal Register of Legislative Instruments F2010L02386, 2010. Department of Health and Ageing. Available from:

50. Furberg H, Lichtenstein P, Pedersen NL, Bulik CM, Lerman C and Sullivan PF. Snus use and other correlates of smoking cessation in the Swedish Twin Registry. Psychological Medicine 2008;38(9):1299-1308. Available from:

51. Lund KE, McNeill A and Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine & Tobacco Research 2010;12(8):817-22. Available from:

52. Lindström M. Nicotine replacement therapy, professional therapy, snuff use and tobacco smoking: a study of smoking cessation strategies in southern Sweden. Tobacco Control 2007;16(6):410-16. Available from:

53. Doran CM, Valenti L, Robinson M, Britt H and Mattick RP. Smoking status of Australian general practice patients and their attempts to quit. Addictive Behaviors 2006;31(5):758-66. Available from:

54. Cobb CO, Weaver MF and Eissenberg T. Evaluating the acute effects of oral, non-combustible Potential Reduced Exposure Products marketed to smokers. Tobacco Control 2010;19(5):367-73. Available from:

55. Blank MD and Eissenberg T. Evaluating oral noncombustible potential-reduced exposure products for smokers. Nicotine & Tobacco Research 2010;12(10):336-43. Available from:

56. Caldwell B, Burgess C and Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine & Tobacco Research 2010;12(2):179-83. Available from:

57. Kotlyar M, Mendoza-Baumgart MI, Li Z-z, Pentel PR, Barnett BC, Feuer RM, et al. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tobacco Control 2007;16(2):138-42. Available from:

58. Rodu B and Phillips CV. Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview Survey. Harm Reduction Journal 2008;5:18. Available from:

59. Carpenter MJ and Gray KM. A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit. Nicotine & Tobacco Research 2010;12(2):136-43. Available from:

60. Tobacco Working Group. Tobacco control in Australia: making smoking history. Prepared for the National Preventative Health Taskforce by the Tobacco Working Group. Technical report (Preventative Health Taskforce Secretariat, Department of Health and Ageing). Canberra: Commonwealth of Australia, 2008. Available from:

61. United States Postal Service. DMM revision: treatment of cigarettes and smokeless tobacco as nonmailable matter, in Postal Bulletin. Washington DC: United States Postal Service, 2010. Available from:

62. Gartner CE and Hall WD. Should Australia lift its ban on low nitrosamine smokeless tobacco products? Medical Journal of Australia 2008;188(1):44-6. Available from:

63. Chapman S. Repealing Australia's ban on smokeless tobacco? Hasten slowly. Medical Journal of Australia 2008;188(1):47–9. Available from:

      Previous Chapter